Blog

Palatin’s PL9588 Shows Promising Glaucoma Treatment Data Exciting new developments in glaucoma treatment are emerging as Palatin Technologies reveals promising data for its investigational drug, PL9588. This novel therapy could offer a breakthrough for millions of patients suffering from glaucoma, a leading cause of irreversible blindness worldwide. With glaucoma affecting over 80 million people globally, […]

Palatin Technologies Reports Promising PL9588 Pre-Clinical Data for Glaucoma Palatin Technologies, a biopharmaceutical company specializing in receptor-targeted therapeutics, has recently unveiled encouraging pre-clinical data for its investigational drug, PL9588, as a potential treatment for glaucoma. This breakthrough could mark a significant advancement in ophthalmology, offering new hope for millions of patients suffering from this sight-threatening

Top Glaucoma Treatments: Medications, Lasers, and Lifestyle Tips Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Often called the “silent thief of sight,” this condition damages the optic nerve, usually due to high intraocular pressure (IOP). While there’s no cure, early diagnosis and proper treatment can slow or prevent vision

How B Vitamins Can Slow Glaucoma Progression Naturally Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. While medical treatments like eye drops and surgery are commonly prescribed, emerging research suggests that B vitamins may play a crucial role in slowing glaucoma progression naturally. This article explores the science behind B

Implantable Glaucoma Device Market Growth Trends and Forecast 2034 The implantable glaucoma device market is poised for significant growth over the next decade, driven by advancements in medical technology, increasing prevalence of glaucoma, and rising demand for minimally invasive surgical options. By 2034, the market is expected to witness substantial expansion, offering new opportunities for

FDC Recalls Over 60,000 Bottles of Glaucoma Medication in US The pharmaceutical industry is no stranger to recalls, but when a critical medication like a glaucoma treatment is involved, the stakes are significantly higher. Recently, FDC (Fera Pharmaceuticals) announced a voluntary recall of more than 60,000 bottles of its glaucoma medication in the United States.

Good Cholesterol May Worsen Glaucoma Risk: New Study Finds For years, high-density lipoprotein (HDL), often referred to as “good cholesterol,” has been celebrated for its role in protecting heart health. However, a groundbreaking new study suggests that elevated levels of HDL may unexpectedly increase the risk of glaucoma—a leading cause of irreversible blindness. This surprising

Early Glaucoma Treatment: MIGS Options Explained by Christine Funke, MD Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Early detection and treatment are crucial to preserving vision and preventing further damage. One of the most promising advancements in glaucoma management is Minimally Invasive Glaucoma Surgery (MIGS). In this article, Dr.

Preventable Glaucoma Vision Loss Hindered by Treatment Costs Glaucoma, often referred to as the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. While early detection and treatment can prevent severe vision loss, the high costs associated with glaucoma care create significant barriers for many patients. This article explores how financial constraints

Glaucoma Therapeutic Market Growth, Key Players, and 2025 Forecast The glaucoma therapeutic market is experiencing significant growth, driven by rising prevalence rates, technological advancements, and increasing awareness about early diagnosis and treatment. Glaucoma, a leading cause of irreversible blindness, affects millions worldwide, making effective therapeutics a critical area of focus for healthcare providers and pharmaceutical